The woman who runs a $2.5 billion fund at Fidelity shares how she went from a Harvard lab to picking out the most promising high-risk, high-reward biotech stocks

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 51%

Business News News

Business Business Latest News,Business Business Headlines

Biotech stocks are notoriously risky. Fidelity biotech fund manager Eirene Kontopoulos told us about her strategy for navigating that volatility.

notoriously riskyMost biotechs are researching treatments, and don't have any medicines available for sale yet, so investors are betting more on the company's vision and science and the team behind it than anything more concrete.

The biotech fund invests in companies of every size, from riskier small-cap biotechs to more established large-cap ones, with an eye to whether they're valued reasonably relative to their financial potential.two out of five stars by Morningstar as of the end of March, a ranking that's based on past performance.

The fund is roughly broken up into three"buckets," with the biggest positions for the most well-established companies, she told Business Insider.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 729. in BUSÄ°NESS

Business Business Latest News, Business Business Headlines